Zealand Pharma Announces Augmentation of its Management Team as it Continues its Growth Strategy
(Thomson Reuters ONE) -
Copenhagen, 8 March 2010
Announcement no. 2, 2010
Today Zealand Pharma A/S announces that Dr. Christian Grøndahl has been
appointed Chief Scientific Officer, Mr. Mats Blom as Chief Financial Officer and
Dr. John Hyttel as Senior Vice President for Operations.
"I am delighted to welcome Christian Grøndahl, Mats Blom and John Hyttel as new
members of Zealand's Management Team. Together they bring a wealth of
experience, energy and skills to Zealand Pharma as we continue to advance our
growth strategy to bring Zealand Pharma A/S to the next level," said Dr. David
Horn Solomon, President and CEO of Zealand Pharma A/S.
Dr. Grøndahl, who will take up his duties as CSO April 1, 2010, has a DVM, PhD
and DMedSci, all from Copenhagen University. Dr. Grøndahl has 20 years of
experience in the medical sciences and has held positions of increasing
responsibility at Novo Nordisk for the past 14 years. Until recently, he was
Corporate Vice President for Strategic Alliances at Novo Nordisk. Dr. Grøndahl
will have overall responsibility for Research and Development at Zealand Pharma
A/S and for commercializing Zealand's strong pipeline of products.
Mr. Blom, whose appointment is effective March 2, 2010, received his BA from
University of Lund and holds an MBA from the University of Navarra in Barcelona,
Spain. Mr. Blom has worked in audit and corporate finance, has been the CFO of
two public companies and until recently was CFO of Swedish Orphan International
that recently merged with Biovitrum to form Swedish Orphan-Biovitrum of
Stockholm. Mr. Blom will be responsible for all financial reporting and for
co-ordinating corporate development finance activities at Zealand Pharma A/S. He
replaces Mr. Mogens Vang Rasmussen who was at Zealand for 7 years, most recently
as COO and CFO.
Dr. Hyttel who began his role as Senior Vice President for Operations on March
1, 2010, is a Founder of Zealand Pharma A/S in 1998. Dr. Hyttel holds degrees
including a MSc and DSc from Copenhagen University. Dr. Hyttel served in
increasing senior positions at H Lundbeck A/S for 30 years prior to joining
Zealand. Dr. Hyttel has also served in senior positions at Zealand, most
recently as Head of Regulatory Affairs. In his new position, Dr. Hyttel will be
responsible for all operational activities at Zealand Pharma A/S.
"With this new strong management team and the deep experience in basic and
clinical science, and commercial and clinical development they bring to the
Company, Zealand Pharma A/S is ready and able to advance its Corporate
Development Strategy " commented Dr. Daan Ellens, Chairman of the Board of
Directors of Zealand Pharma A/S.
Zealand's most advanced project, Lixisenatide (ZP10/AVE0010), a GLP-1 agonist
for the treatment of Type II Diabetes has been out licensed to Sanofi-Aventis of
France. Sanofi-Aventis is completing 9 Phase III trials with first results to be
released in June 2010. Sanofi-Aventis is also commercializing a
Lantus-Lixisenatide combination product for the treatment of Type II Diabetes
that has completed Phase I clinical studies. Submission of IND/MAA for
Lixisenatide is expected in 2011.
# # #
Further information
David Solomon, President and Chief Executive Officer
Zealand Pharma A/S, Smedeland 36, DK-2600 Glostrup, Denmark
T +45 4328 1200 F +45 4328 1212 E info(at)zp.dk
About Zealand Pharma
Zealand Pharma is a biopharmaceutical company dedicated to the discovery and
development of innovative peptide-based drugs. Zealand is one of the leaders
within the peptide area, a growing market with significant drug development
activities including treatment of metabolic and cardiovascular diseases. All of
Zealand's products target diseases and symptoms of significant unmet clinical
need and commercial potential.
Since 1999, Zealand's scientists have built a pipeline that includes five
compounds in clinical development, four of which have been out licensed, three
of these to major pharmaceutical companies (Sanofi-Aventis, Wyeth and Helsinn
Healthcare). All Zealand's compounds emerge from Zealand's own drug discovery.
* Lixisenatide (AVE0010/ZP10), a pharmaceutical agent for the treatment of
Type 2 Diabetes, has been out-licensed to Sanofi-Aventis, which is the
world's third largest pharmaceutical corporation with a strong Diabetes
franchise. Phase III clinical trials were initiated in May 2008.
* GAP-134/ZP1609; a gap junction modifier that prevents both ventricular and
atrial arrhythmias in animal models. With its oral formulation, the molecule
represents a novel paradigm for the potential chronic prevention of atrial
arrhythmias. US based pharmaceutical giant Wyeth Pharmaceutical has
finalized a Phase I trial in the US.
* ZP1846 is an innovative treatment for prevention of chemotherapy-induced
diarrhea, which may prevent discontinuation and dose modification during
cancer chemotherapy. A Phase I clinical trial has been conducted in the US.
The compound has been partnered with Helsinn Healthcare SA.
* ZP1848 is a novel paradigm for the treatment of Inflammatory Bowel Diseases
(e.g. Crohn's Disease). The compound has completed Phase I clinical
development in the US.
* AP214/ZP1480 for Post-surgical Organ Failure, partnered with Action Pharma,
currently in clinical Phase II development.
In addition, Zealand has a rich and broad portfolio of pre-clinical projects
targeting a variety of disease areas, including osteoporosis and obesity-related
Diabetes.
Zealand Pharma A/S is based in Copenhagen and has approximately 65 employees.
The Company's investors include LD Pensions, Dansk Erhvervsinvestering and
Sunstone Capital as well as the leading international biotech investors CDC
Innovation and Allianz Private Equity (both in Paris) and LSP (Amsterdam).
[HUG#1391617]
Press Release in PDF: http://hugin.info/136974/R/1391617/349440.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="Terra Ventures Inc.: Hathor Completes the First Drill Fence at the Roughrider Zone East Discovery">
" alt="Cypress & Skyharbour Drilling Update on Broulan Reef Bruce Channel / Red Lake Gold Project">
Datum: 08.03.2010 - 05:25 Uhr
Sprache: Deutsch
News-ID 1010913
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Glostrup
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 75 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Zealand Pharma Announces Augmentation of its Management Team as it Continues its Growth Strategy
"
steht unter der journalistisch-redaktionellen Verantwortung von
Zealand Pharma (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
